Uber stock surges after Nvidia partnership announcement
Tenon Medical, Inc. (NASDAQ:TNON) reported on Monday that it granted a total of 866,642 restricted stock units (RSUs) to its directors and officers. The awards were made under the company’s 2022 Equity Incentive Plan, as amended.
According to a statement in the company’s SEC filing, the RSUs will vest in two equal installments, with 50% vesting on January 1, 2026, and the remaining 50% vesting on July 31, 2026. Upon vesting, each RSU will automatically convert into one share of Tenon Medical’s common stock.
The company stated that these RSUs were issued in reliance on an exemption from registration under Section 4(a)(2) of the Securities Act of 1933, as the transaction did not involve a public offering of securities.
Tenon Medical , based in Los Gatos, California, is listed on the Nasdaq Stock Market under the tickers TNON for its common stock and TNONW for its warrants. The information is based on a press release statement included in the company’s recent SEC filing.
In other recent news, Tenon Medical reported its financial results for the second quarter of 2025, revealing a decline in revenue but an improved net loss compared to the previous year. The company’s strategic acquisitions and product innovations, including FDA clearance for new medical devices, have contributed to a promising outlook for future quarters. Additionally, Tenon Medical has launched the Catamaran SE SI Joint Fusion System, a smaller implant option for sacroiliac joint fusion procedures, enhancing its product portfolio. This new device offers surgeons more flexibility, particularly for patients with smaller SI joint anatomy or in revision surgeries.
Furthermore, Tenon Medical held its 2025 Annual Meeting of Stockholders virtually, where several proposals were submitted to a vote after meeting quorum requirements. The meeting was initially adjourned in July and August due to a lack of quorum but reconvened with a new record date of August 22, 2025. These developments reflect Tenon Medical’s ongoing efforts to innovate and address market demands while engaging with its shareholders.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.